Design Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Design Therapeutics, Inc. (DSGN) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $6.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2025-03-10
- Design Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-12-31 was -$3.00K, a 160.00% decline year-over-year.
- Design Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-09-30 was $1.00K, a 87.50% decline year-over-year.
- Design Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-06-30 was $4.00K, a 60.00% decline year-over-year.
- Design Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-03-31 was $4.00K, a 60.00% decline year-over-year.
- Design Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $6.00K, a 81.82% decline from fiscal 2023.
- Design Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $33.00K, a 45.00% decline from fiscal 2022.
- Design Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $60.00K, a 215.79% increase from fiscal 2021.
- Design Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $19.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$2.00K derived: sum of 2 quarters · filed 2025-03-10 | $2.00K derived: sum of 3 quarters · filed 2025-03-10 | $6.00K 10-K · filed 2025-03-10 |
| 2024-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $5.00K derived: sum of 2 quarters · filed 2024-11-07 | $9.00K 10-Q · filed 2024-11-07 | $14.00K derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $8.00K 10-Q · filed 2024-08-05 | $13.00K derived: sum of 3 quarters · filed 2025-03-10 | $21.00K derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-03-31 | $4.00K 10-Q · filed 2024-05-08 | $9.00K derived: sum of 2 quarters · filed 2025-03-10 | $17.00K derived: sum of 3 quarters · filed 2025-03-10 | $27.00K derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $13.00K derived: sum of 2 quarters · filed 2025-03-10 | $23.00K derived: sum of 3 quarters · filed 2025-03-10 | $33.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $18.00K derived: sum of 2 quarters · filed 2024-11-07 | $28.00K 10-Q · filed 2024-11-07 | $39.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $20.00K 10-Q · filed 2024-08-05 | $31.00K derived: sum of 3 quarters · filed 2024-08-05 | $45.00K derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $10.00K 10-Q · filed 2024-05-08 | $21.00K derived: sum of 2 quarters · filed 2024-05-08 | $35.00K derived: sum of 3 quarters · filed 2024-05-08 | $56.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $25.00K derived: sum of 2 quarters · filed 2024-03-19 | $46.00K derived: sum of 3 quarters · filed 2024-03-19 | $60.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $35.00K derived: sum of 2 quarters · filed 2023-11-13 | $49.00K 10-Q · filed 2023-11-13 | $63.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $35.00K 10-Q · filed 2023-08-14 | $49.00K derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | $14.00K 10-Q · filed 2023-05-09 | $28.00K derived: sum of 2 quarters · filed 2023-05-09 | ||
| 2021-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $19.00K 10-K · filed 2023-03-14 | ||
| 2021-09-30 | $5.00K 10-Q · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |